Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer
pharmafile | December 12, 2019 | News story | Business Services | Journal of Medicine, Novartis, menopause
Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in risk of death compared to fulvestrant on its own in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
This data was published in The New England Journal of Medicine (NEJM).
Jeff Engelman, Global Head of Oncology Research at Novartis Institutes for BioMedical Research, said: “These data show that treatment with Kisqali gives women with HR+/HER2- advanced breast cancer a chance for more life – whether they are treatment naïve or have had prior therapy. Pre-clinical data show that Kisqali is distinct from other CDK4/6 inhibitors in its ability to more selectively target and inhibit CDK4.”
The NEJM publication includes subgroup analyses according to a line of therapy. At 42 months, survival rates among patients who received first-line therapy were 66.9% with Kisqali plus fulvestrant vs 56.3% with fulvestrant alone. The median survival rates among patients in the early-relapse and second-line subgroup was 40.2 months with Kisqali plus fulvestrant and 32.5 months with fulvestrant alone.
A post-hoc survival analysis based on prior endocrine therapy demonstrated that Kisqali plus fulvestrant had a 36% reduction in rick in death for those who did not receive any previous endocrine therapy, a 30% reduction in risk of death in those who were endocrine resistant and a 26% reduction in risk of death in those who were endocrine sensitive.
Kisqali is a prescription medicine that is used in combination with an aromatase inhibitor that is the first hormonal-based therapy to treat pre and postmenopausal women.
Conor Kavanagh
Related Content
PeptiDream and Novartis extend peptide discovery collaboration
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Novartis shares new data for Zolgensma in children with SMA
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …
